Niclosamide (BAY2353) olamine 是一种具有口服活性的用于寄生虫感染研究的抗蠕虫化合物。Niclosamide olamine 是STAT3抑制剂,在 HeLa 细胞中的IC50为 0.25 μM。Niclosamide olamine 具有抗癌的生物活性,并能抑制 Vero E6 细胞的 DNA 复制。
生物活性 | Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasiticinfectionresearch[1]. Niclosamide olamin is aSTAT3inhibitor with anIC50of 0.25 μM in HeLa cells[4]. Niclosamide olamin has biological activities againstcancer, and inhibits DNA replication in Vero E6 cells[2][3][5]. |
体外研究 (In Vitro) | 氯硝柳胺 (0.6 nM-46 μ M) 处理可抑制 BD140A、SW-13 和 NCI-H295R 细胞的肾上腺皮质癌细胞增殖[3]。 氯硝柳胺 (0.05-5 μM, 24 h) 处理抑制 STAT3 介导的 HeLa 细胞荧光素酶报告活性[4]。 氯硝柳胺 (10 μM) 处理抑制病毒在 Vero E6 细胞中的复制[5]。
Cell Viability Assay[3] Cell Line: | BD140A, SW-13 and NCI-H295R cells | Concentration: | 0.6 nM-46 μM | Incubation Time: | | Result: | Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50of 0.12 μM, 0.15 μM, and 0.53 μM in BD140A, SW-13, and NCI-H295R, respectively. |
Cell Viability Assay[4] Cell Line: | Hela cells | Concentration: | 0.05-5 μM | Incubation Time: | 24 hours | Result: | Inhibited STAT3-mediated luciferase reporter activity with an IC50of 0.25 μM. |
Cell Viability Assay[5] Cell Line: | Vero E6 cells | Concentration: | 10 μM | Incubation Time: | 2 days | Result: | Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells. |
|
体内研究 (In Vivo) | 氯硝柳胺钠 (灌胃; 100 mg/kg, 200 mg/kg;一周一次; 8周) 治疗抑制肾上腺皮质癌肿瘤在体内生长[3]。
Animal Model: | Nu+/Nu+mice injected with NCI-H295R cells[3] | Dosage: | 100 mg/kg, 200 mg/kg | Administration: | Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks | Result: | Showed a 60%-80% inhibition in tumor growth, as compared to the control group. |
|
Clinical Trial | |
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |